Intravenous immunoglobulin (IVIG) is a common prophylactic treatment in patients with multiple myeloma (MM). Synthesized from large groups of individuals, IVIG consists of the proteins in blood plasma. These proteins can help immunocompromised individuals, such as those who have MM, fight off infections.
In a terrific video from the HealthTree Foundation for Multiple Myeloma, Dr. Urvi Shah, a hematologist at the Memorial Sloan Kettering Cancer Center, answers many of the common questions patients have about IVIG. Some of the topics covered include administration techniques, side effects, indications and counterindications, blood type matching, and hyperimmunoglobulin (IVIG targeted against a specific illness).
This video is essential content for nurses, who are often tasked with explaining treatment indications, outcomes, methods, and side effects to their patients.
To watch the video, visit the HealthTree Foundation “Know Your Therapy” course site, and select course 12.22.
Reference
Know your therapy: IVIG – The HealthTree Foundation for Multiple Myeloma
